A Phase 3 interventional study of OPC-41061 and OPC-41061 in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-04.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics, efficacy, and safety will be investigated.
1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.
This study's enrollment of 40 is below the median of 63 across 841 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with any of the following complications or symptoms:
Patients with a history of any of the following disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily oral administration of OPC-41061
Drug: OPC-41061
Once-daily oral administration of OPC-41061
Drug: OPC-41061
Body Weight
Changes from baseline (day-1) for body weight at the end of treatment (LOCF) were calculated.
Time frame: Bseline, Day 7 or at the discontined of treatment
Ascites Volume as Measured by CT
Change from baseline (day-1) for ascites volume as measured by CT at the end of treatment (LOCF) were calculated.
Time frame: Baseline, Day 7 or at the discontinued of treatment
| Milestone | 3.75 mg | 7.5 mg |
|---|---|---|
| Started | 19 | 21 |
| Completed | 16 | 17 |
| Not completed | 3 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Changes from baseline (day-1) for body weight at the end of treatment (LOCF) were calculated.
| kg | OPC-41061 3.75 mg | OPC-41061 7.5 mg |
|---|---|---|
| Body Weight | -1.14 ± 0.86 | -1.37 ± 2.05 |
Change from baseline (day-1) for ascites volume as measured by CT at the end of treatment (LOCF) were calculated.
| mL | OPC-41061 3.75 mg | OPC-41061 7.5 mg |
|---|---|---|
| Ascites Volume as Measured by CT | -407.5 ± 545.8 | -514.0 ± 993.8 |
Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3.75 mg | — | 2/19 (10.5%) | 13/19 (68.4%) |
| 7.5 mg | — | 3/21 (14.3%) | 15/21 (71.4%) |
| Event | 3.75 mg | 7.5 mg |
|---|---|---|
| Hepatic EncephalopathyNervous system disorders | 1/19 | 2/21 |
| Gastrointestinal Angiodysplasia HaemorrhagicCongenital, familial and genetic disorders | 1/19 | 0/21 |
| Gastric Ulcer HaemorrhageGastrointestinal disorders | 1/19 | 0/21 |
| AscitesGastrointestinal disorders | 0/19 | 1/21 |
| Blood Potassium IncreasedInvestigations | 0/19 | 1/21 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/19 | 1/21 |
| Event | 3.75 mg | 7.5 mg |
|---|---|---|
| ThirstGeneral disorders | 3/19 | 7/21 |
| Blood Pressure DecreasedInvestigations | 3/19 | 0/21 |
| Skin ExfoliationSkin and subcutaneous tissue disorders | 3/19 | 1/21 |
| NauseaGastrointestinal disorders | 2/19 | 1/21 |
| VomitingGastrointestinal disorders | 2/19 | 0/21 |
| PyrexiaGeneral disorders | 2/19 | 1/21 |
| ExcoriationInjury, poisoning and procedural complications | 2/19 | 0/21 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 2/19 | 0/21 |
| Blood Potassium IncreasedInvestigations | 2/19 | 0/21 |
| Blood Urine PresentInvestigations | 2/19 | 1/21 |
| Age, Continuous(years) | 3.75 mg | 7.5 mg | Total |
|---|---|---|---|
| Mean | 67.3 ± 9.3 | 64.2 ± 10.4 | 65.7 ± 9.9 |
| Age, Categorical(Participants) | 3.75 mg | 7.5 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 11 | 18 |
| >=65 years | 12 | 10 | 22 |
| Sex: Female, Male(Participants) | 3.75 mg | 7.5 mg | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 14 | 13 | 27 |
| Region of Enrollment(participants) | 3.75 mg | 7.5 mg | Total |
|---|---|---|---|
| Japan | 19 | 21 | 40 |
The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →